Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
First Claim
Patent Images
1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
-
wherein;
R is alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, bicycloalkenylalkyl, tricycloalkenylalkyl, tetracycloalkenylalkyl, bicycloalkenoxyalkyl, tricycloalkenoxyalkyl, tetracycloalkenyloxyalkyl, cycloalkylalkenyl, cycloalkylalkynyl, aralkenyl, aralkynyl, substituted aralkyl, aralkoxyalkyl, aralkoxyalkenyl, aralkoxyalkynyl, aralkenoxyalkyl, aralkenoxyalkenyl, heteroarylalkyl, heterocyclooxyalkyl, heterocyclothiaalkyl, heterocycloalkenyl, heteroarylalkenyl, heteroarylalkynyl, aryloxyalkyl, aryloxyalkenyl, aryloxyalkynyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkenyl, dihydroxyalkenyl, hydroxyalkynyl, haloalkyloxyalkyl, haloalkoxyalkenyl, haloalkoxyalkynyl, carbonyl, cycloalkyloxyalkyl, cycloalkylalkyloxyalkyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonylalkyl, arylalkylcarbonyl, arylalkenylcarbonyl, arylalkyloxycarbonyl, aryloxyalkylcarbonyl, aryloxyalkylcarbonyl, haloalkylcarbonyl, hydroxyalkylcarbonyl, haloalkyloxyalkylcarbonyl, cycloalkyloxyalkylcarbonyl, alkoxyalkylcarbonyl, alkyloxycarbonyl, alkanoyloxyalkyl, aryloxyalkoxyalkyl, aroyloxyalkyl, aminoalkyl, amino(alkyl), alkanoylaminoalkyl, hydroxysulfonealkyl, aminosulfonealkyl, aminocarbonylaminoalkyl, aroylaminoalkyl, alkoxycarbonylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, perhaloalkylaralkyl, or R5, wherein R5=R1X1(R2X2)m(R3X3)n(R4X4)pR6—
wherein;
R1 is alkyl, aryl, alkenyl, alkynyl, hydrogen or haloalkyl;
R2 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R3 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R4 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R6 is independently alkylene, alkenylene, alkynylene or haloalkylene;
X1 is independently oxygen, sulfur, sulfoxide or sulfone;
X2 is independently oxygen, sulfur, sulfoxide or sulfone;
X3 is independently oxygen, sulfur, sulfoxide or sulfone;
X4 is independently oxygen, sulfur, sulfoxide or sulfone;
m, n and p are independently 0, 1, 2, or 3; and
m+n+p≦
3 A, B, C, and D are independently hydrido, lower alkyl, lower haloalkyl or acyl;
D and R taken together may form a five or six membered ring when R is carbonyl or alkylcarbonyl;
A and B taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
B and C taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring; and
C and D taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
wherein the main chain in R contains between one and twenty atoms; and
the main chain of R5 containing between four and twenty atoms.
4 Assignments
0 Petitions
Accused Products
Abstract
N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulats or various combinations of such other agents.
96 Citations
27 Claims
-
1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
-
wherein; R is alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, bicycloalkenylalkyl, tricycloalkenylalkyl, tetracycloalkenylalkyl, bicycloalkenoxyalkyl, tricycloalkenoxyalkyl, tetracycloalkenyloxyalkyl, cycloalkylalkenyl, cycloalkylalkynyl, aralkenyl, aralkynyl, substituted aralkyl, aralkoxyalkyl, aralkoxyalkenyl, aralkoxyalkynyl, aralkenoxyalkyl, aralkenoxyalkenyl, heteroarylalkyl, heterocyclooxyalkyl, heterocyclothiaalkyl, heterocycloalkenyl, heteroarylalkenyl, heteroarylalkynyl, aryloxyalkyl, aryloxyalkenyl, aryloxyalkynyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkenyl, dihydroxyalkenyl, hydroxyalkynyl, haloalkyloxyalkyl, haloalkoxyalkenyl, haloalkoxyalkynyl, carbonyl, cycloalkyloxyalkyl, cycloalkylalkyloxyalkyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonylalkyl, arylalkylcarbonyl, arylalkenylcarbonyl, arylalkyloxycarbonyl, aryloxyalkylcarbonyl, aryloxyalkylcarbonyl, haloalkylcarbonyl, hydroxyalkylcarbonyl, haloalkyloxyalkylcarbonyl, cycloalkyloxyalkylcarbonyl, alkoxyalkylcarbonyl, alkyloxycarbonyl, alkanoyloxyalkyl, aryloxyalkoxyalkyl, aroyloxyalkyl, aminoalkyl, amino(alkyl), alkanoylaminoalkyl, hydroxysulfonealkyl, aminosulfonealkyl, aminocarbonylaminoalkyl, aroylaminoalkyl, alkoxycarbonylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, perhaloalkylaralkyl, or R5, wherein R5=R1X1(R2X2)m(R3X3)n(R4X4)pR6—
wherein;
R1 is alkyl, aryl, alkenyl, alkynyl, hydrogen or haloalkyl;
R2 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R3 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R4 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R6 is independently alkylene, alkenylene, alkynylene or haloalkylene;
X1 is independently oxygen, sulfur, sulfoxide or sulfone;
X2 is independently oxygen, sulfur, sulfoxide or sulfone;
X3 is independently oxygen, sulfur, sulfoxide or sulfone;
X4 is independently oxygen, sulfur, sulfoxide or sulfone;
m, n and p are independently 0, 1, 2, or 3; and
m+n+p≦
3A, B, C, and D are independently hydrido, lower alkyl, lower haloalkyl or acyl;
D and R taken together may form a five or six membered ring when R is carbonyl or alkylcarbonyl;
A and B taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
B and C taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring; and
C and D taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
wherein the main chain in R contains between one and twenty atoms; and
the main chain of R5 containing between four and twenty atoms. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
26. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
-
wherein R is selected from the group consisting of alkenylcarbonyl, alkynylcarbonyl, arylalkylcarbonyl, aryloxyalkyl, aryloxyalkylcarbonyl, haloalkylcarbonyl, hydroxyalkylcarbonyl, haloalkyloxyalkylcarbonyl, cycloalkyloxyalkylcarbonyl, alkoxyalkylcarbonyl, cycloalkylalkylcarbonyl, alkoxycarbonyl, alkylcarbonyl, aryloxyalkoxyalkylcarbonyl, alkylcarbonyloxyalkylcarbonyl, arylcarbonyloxyalkylcarbonyl, aminoalkylcarbonyl, alkylcarbonylaminoalkylcarbonyl, arylcarbonylaminoalkylcarbonyl, alkoxycarbonylaminoalkylcarbonyl, aminocarbonylaminoalkylcarbonyl, aminothiocarbonylaminoalkylcarbonyl, arylalkenylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, aminocarbonylalkylcarbonyl, aminothiocarbonylalkylcarbonyl, aminosulfonealkylcarbonyl, arylalkynylcarbonyl, heterocycloalkylcarbonyl, heteroarylalkylcarbonyl, heteroaryloxyalkylcarbonyl, heteroarylthiaalkylcarbonyl, heterocyclooxyalkylcarbonyl, heterocyclothiaalkylcarbonyl, arylthiaalkylcarbonyl, monohaloalkylcarbonyl, haloalkyloxyalkylcarbonyll, cycloalkylalkyloxyalkylcarbonyl or R5 carbonyl wherein;
R5=R1X1(R2X2)m(R3X3)n(R4X4)pR6—
whereinR1 is alkyl, aryl, alkenyl, alkynyl, hydrogen or haloalkyl;
R2 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R3 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R4 is independently alkylene, alkenylene, alkynylene or haloalkylene;
R6 is independently alkylene, alkenylene, alkynylene or aloalkylene;
X1 is independently oxygen, sulfur, sulfoxide or sulfone;
X2 is independently oxygen, sulfur, sulfoxide or sulfone;
X3 is independently oxygen, sulfur, sulfoxide or sulfone;
X4 is independently oxygen, sulfur, sulfoxide or sulfone;
m, n and p are independently 0, 1, 2, or 3;
(m+n+p)≦
3;
(m+n+p)≧
1;
when all of any X1, X2, X3, and X4 linkages are oxygen;
(m+n+p)≧
2; and
R1 is not hydrogen or unsubstituted alkyl;
or not all of any R2, R3 and R4 groups are unsubstituted alkylene;
A, B, C, and D are independently hydrido, lower alkyl, lowerhaloalkyl or acyl;
D and R taken together may form a five or six membered ring when R is carbonyl or alkylcarbonyl;
A and B taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
B and C taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
C and D taken together with the atoms to which they are attached may form a five or six membered heterocyclic ring;
wherein the main chain in R contains between one and twenty atoms;
the main chain of R5 containing between four and twenty atoms;
when all of any X1, X2, X3, and X4 linkages are oxygen; and
(m+n+p)≧
2; and
R1 is not hydrogen or unsubstituted alkyl;
or not all of any R2, R3 and R4 groups are unsubstituted alkylene.- View Dependent Claims (27)
-
Specification